Unknown

Dataset Information

0

Venetoclax enhances T cell-mediated antileukemic activity by increasing ROS production.


ABSTRACT: Venetoclax, a Bcl-2 inhibitor, in combination with the hypomethylating agent azacytidine, achieves complete remission with or without count recovery in ∼70% of treatment-naive elderly patients unfit for conventional intensive chemotherapy. However, the mechanism of action of this drug combination is not fully understood. We discovered that venetoclax directly activated T cells to increase their cytotoxicity against acute myeloid leukemia (AML) in vitro and in vivo. Venetoclax enhanced T-cell effector function by increasing reactive oxygen species generation through inhibition of respiratory chain supercomplexes formation. In addition, azacytidine induced a viral mimicry response in AML cells by activating the STING/cGAS pathway, thereby rendering the AML cells more susceptible to T cell-mediated cytotoxicity. Similar findings were seen in patients treated with venetoclax, as this treatment increased reactive oxygen species generation and activated T cells. Collectively, this study presents a new immune-mediated mechanism of action for venetoclax and azacytidine in the treatment of AML and highlights a potential combination of venetoclax and adoptive cell therapy for patients with AML.

SUBMITTER: Lee JB 

PROVIDER: S-EPMC8310428 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4742825 | biostudies-other
| S-EPMC6613841 | biostudies-literature
| S-EPMC3976863 | biostudies-literature
| S-EPMC8197764 | biostudies-literature
| S-EPMC7876886 | biostudies-literature
| S-EPMC6744942 | biostudies-literature
| S-EPMC6351127 | biostudies-literature
| S-EPMC5303887 | biostudies-other
2022-07-22 | MSV000089945 | MassIVE
2022-07-22 | MSV000089944 | MassIVE